Population pharmacokinetics of imipenem in burn patients

Fundamental and Clinical Pharmacology

Volumn 17, Issue 6, 2003, Pages 645-650

  Dailly, Eric ^a   Kergueris, Marie France ^a   Pannier, Michel ^a   Jolliet, Pascale ^a   Bourin, Michel ^a  

^a HÔTEL DIEU   (France)

Author keywords

Burns; Drug dosage; Imipenem; Pharmacokinetics; Population

Indexed keywords

CREATININE; IMIPENEM;

ADULT; AGE; BODY HEIGHT; BODY WEIGHT; BURN; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG MONITORING; FEMALE; GENDER; GLOMERULUS FILTRATION RATE; HUMAN; LUNG DISEASE; MALE; PRIORITY JOURNAL; PROCESS MODEL; REVIEW; SEPTICEMIA;

BURNS; CREATININE; HUMANS; IMIPENEM; INJECTIONS, INTRAVENOUS; METABOLIC CLEARANCE RATE; RETROSPECTIVE STUDIES;

EID: 0345376133     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1472-8206.2003.00190.x     Document Type: Review

References (14)

1. Buckley M.M., Brogden R.N., Barradell L.B., Goa K.L. Imipenem/cilastatin: a reappraisal of its antibacterial activity, pharmacokinetics properties and therapeutic efficacy. Drugs (1992) 44 408-144.
2. Jaehde U., Sörgel F. Clinical pharmacokinetics in patients with burns. Clin. Pharmacokinet. (1995) 29 15-28.
3. Weinbren M.J. Pharmacokinetics of antibiotics in burn patients. J. Antimicrob. Chemother. (1999) 44 319-327.
4. Boucher B.A., Hickerson W.L., Kuhl D.A., Bombassaro A.M., Jaresko G.S. Imipenem pharmacokinetics in patients with burns. Clin. Pharmacol. Ther. (1990) 48 130-137.
5. Bustamante C.I., Drusano G.L., Tatem B.A., Standiford H.C. Post antibiotic effect of imipenem in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. (1984) 26 678-682.
6. Munckhof W.J., Olden D., Trunidge J.D. The post antibiotic effect of imipenem: relationship with drug concentration, duration of exposure and MIC. Antimicrob. Agents Chemother. (1997) 41 1735-1737.
7. Hessen M.T., Pitsakis P.G., Levison M.E. Absence of a post-antibiotic effect in experimental Pseudomonas endocarditis treated with imipenem, with or without gentamicin. J. Infect. Dis. (1988) 158 542-548.
8. Majcherczyk P.A., Kunz S., Hattenberg M., Vaxelaire J., Zak O., O'Reilly T. Isolation and in vitro-characterisation of a mutant of Pseudomonas aeruginosa PAO1 that exhibited a reduced post-antibiotic effect in response to imipenem. J. Antimicrob. Chemother. (1994) 34 485-505.
9. Gravallese D.A., Musson D.G., Pauliukonis L.T., Bayne W.F. Determination of imipenem (N-formimidoyl Thienamycin) in human plasma and urine by high-performance liquid chromatography, comparison with microbiological methodolgy and stability. J. Chromatogr. (1984) 310 71-84.
10. Micropharm Population (MP2). Version 5.5. Institut National de la Science et de la Recherche Médicale. Paris, 1994.
11. Sheiner L.B., Beal S.L. Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. J. Pharmacokinet. Biopharm. (1980) 8 553-571.
12. Clissold S.P., Todd P.A., Campoli-Richard D.M. Imipenem/cilastatin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs (1987) 33 183-241.
13. Toon S., Hopkins K.J., Garstang F.M., Aarons L., Rowland M. Pharmacokinetics of imipenem and cilastatin after their simultaneous administration to the elderly. Br. J. Clin. Pharmacol. (1987) 23 143-149.
14. Walstad R.A., Aanderud L., Thurman-Nielsen E. Pharmacokinetics and tissue concentrations of ceftazidime in burn patients. Eur. J. Clin. Pharmacol. (1988) 35 543-549.